Lupus (systemic lupus erythematosus, SLE) is a systemic autoimmune disease affecting skin, joints, kidneys, heart, and other organs. Flares alternate with remission. Most patients are women of childbearing age. Treatment suppresses immune activation and prevents organ damage.
Hydroxychloroquine (Plaquenil) is foundational—used in nearly all SLE patients to reduce flares, manage skin and joint symptoms, and protect organs. NSAIDs treat pain and joint inflammation. Low-dose corticosteroids reduce systemic inflammation; doses are minimised to avoid long-term toxicity. Immunosuppressants (mycophenolate, azathioprine, cyclophosphamide) are reserved for severe organ involvement (nephritis, vasculitis, CNS lupus). Newer monoclonal antibodies targeting complement (belimumab) and B cells reduce flare frequency. Screening for renal involvement, cardiac risk, and bone density is routine. Pregnancy planning involves liaison with rheumatology.
Herbal supplements (andrographis, proprietary Chinese medicine blends) are used by some patients but lack robust evidence. Strict UV avoidance, adequate rest, and stress reduction are lifestyle essentials, not alternatives to pharmacotherapy.
Stem cell therapy is highly experimental in lupus. Mesenchymal stem cells theoretically suppress aberrant immune responses; early preclinical work is promising but clinical evidence is minimal. Autologous haematopoietic stem cell transplantation has been explored in severe, refractory lupus but carries substantial procedural risk. Regenerative approaches are not standard.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Hydroxychloroquine (Plaquenil) | Standard | Strong | €80–150/month | Low | Continuous; foundation therapy; ophthalmology monitoring required |
| NSAIDs (Ibuprofen, Naproxen) | Standard | Strong | €30–70/month | Low | Rapid symptom relief; used with gastric protection |
| Low-Dose Corticosteroids (Prednisone) | Standard | Strong | €40–80/month | Low | Rapid anti-inflammatory effect; minimised to reduce long-term toxicity |
| Mycophenolate Mofetil (Immunosuppressant) | Standard | Strong | €200–400/month | Low | Protects kidneys and organs; used in severe lupus nephritis |
| Belimumab (Benlysta—Anti-B-cell Biologic) | Standard | Moderate | €2,000–3,500/month | Low | Monthly IV infusions; reduces flares by 20–30% |
| Cyclophosphamide (Severe Vasculitis, CNS Lupus) | Standard | Strong | €1,500–3,000 per infusion | Medium | IV infusions over months; significant toxicity risk; reserved for severe disease |
| Mesenchymal Stem Cell Infusion | Regenerative | Investigational | €20,000–40,000 | Medium | 1–2 weeks; long-term immunosuppression unproven |
| UV Protection & Lifestyle Modification | Standard | Strong | €50–150/year (sunscreen, clothing) | Low | Immediate; reduces flares when combined with pharmacotherapy |
No cure exists, but most patients achieve sustained remission with hydroxychloroquine and corticosteroids ± immunosuppressants. Some taper medications; flares may recur. Modern therapy enables normal life expectancy for most.
Stem cell therapy is investigational. Mesenchymal cells may suppress aberrant B-cell and T-cell responses theoretically; clinical trials are minimal. Established immunosuppression is the current standard.
With proper planning and treatment, many women with lupus have successful pregnancies. Hydroxychloroquine and some immunosuppressants are safe in pregnancy. Close rheumatology and obstetric liaison is essential; flares increase risk.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估